Can Fam Physician. 2020 Dec;66(12):895-897. doi: 10.46747/cfp.6612895.
A few patients have previously presented to my clinic with palpable purpura, joint inflammation, and severe abdominal pain characteristic of Henoch-Schönlein purpura (HSP). Considering that renal injury is the primary long-term complication of HSP, are corticosteroids effective in preventing or treating renal disease in children with HSP?
Henoch-Schönlein purpura is self-limiting in 94% of children, but permanent renal injury is reported in one-fifth of children with nephritic or nephrotic features. Corticosteroids have been considered as candidates for preventing and treating renal involvement in HSP. There is a moderate level of evidence to suggest corticosteroids are not effective in preventing renal involvement in HSP. However, based on low-level evidence and similarities with primary immunoglobulin A nephropathy, experts recommend corticosteroids in treating renal involvement in HSP to prevent long-term kidney injury. Dose and duration of therapy should be carefully considered in consultation with a pediatric nephrologist.
我的诊所曾有几位患者出现可触及的紫癜、关节炎症和典型的过敏性紫癜(HSP)的剧烈腹痛。鉴于肾脏损伤是 HSP 的主要长期并发症,皮质类固醇是否可有效预防或治疗 HSP 患儿的肾脏疾病?
HSP 在 94%的儿童中为自限性疾病,但有肾病或肾病特征的儿童中,有五分之一报告存在永久性肾脏损伤。皮质类固醇类药物一直被认为是预防和治疗 HSP 肾脏受累的候选药物。有中等质量的证据表明皮质类固醇类药物不能有效预防 HSP 的肾脏受累。但是,基于低水平证据以及与原发性免疫球蛋白 A 肾病的相似性,专家建议在治疗 HSP 的肾脏受累时使用皮质类固醇类药物,以预防长期肾脏损伤。应在与儿科肾病专家协商后仔细考虑治疗的剂量和时间。